DEFA14A: Walgreens Boots Alliance Issues Supplemental Merger Disclosures Amid Shareholder Lawsuits

Walgreens Boots Alliance has filed supplemental disclosures to its definitive proxy statement concerning its merger with Blazing Star Parent, LLC, in response to shareholder lawsuits alleging material omissions and misrepresentations.

Summary

• Walgreens Boots Alliance, Inc. (WBA) filed supplemental disclosures to its definitive proxy statement (Schedule 14A) regarding its merger with Blazing Star Parent, LLC, a transaction scheduled for a stockholder vote on July 11, 2025.
• Two lawsuits, Drulias v. Babiak, et al. (filed June 16, 2025) and Johnson v. Walgreens Boots Alliance, Inc., et al. (filed June 18, 2025), along with 11 demand letters, allege that the Definitive Proxy Statement misrepresents and/or omits material information concerning financial projections, analyses by financial advisors, alleged conflicts of interest, and the merger process.
• WBA denies the claims but is voluntarily providing these supplemental disclosures to address the plaintiffs' claims and avoid potential nuisance, expense, and business delays.
• The supplemental disclosures amend and restate sections of the Definitive Proxy Statement, including 'Special Factors—Background of the Merger,' 'Special Factors—Opinion of the Financial Advisors to the Board,' and 'Special Factors—Certain Unaudited Prospective Financial Information.'
• Key financial projections (February, October, and December Projections, and VMD Forecasts) for fiscal years 2025E through 2029E (or 2030E for VMD) are detailed, including Revenue, Adjusted EBITDA, Adjusted Operating Income, Unlevered Free Cash Flow, and Free Cash Flow.
• Centerview's valuation analyses resulted in implied per share equity value ranges: DAP Right $1.33 to $1.99 (after a 30% risk adjustment), Selected Public Company $4.60 to $12.70, Select Precedent Transaction $6.90 to $15.20, and Discounted Cash Flow $10.80 to $19.10.
• Morgan Stanley's Public Trading Comparables analysis implied a per share value range of $7.95 to $12.25 for CY2025E Adjusted EPS.
• The Implied Consideration Value to be received by holders of Company Common Stock is $12.64 to $13.36 per share.
• The Board observed a decline in the company's adjusted operating income and free cash flow since 2022 due to headwinds in the U.S. retail pharmacy and healthcare businesses.
• The Board noted that expected free cash flow would be insufficient to cover the historical $1.00 per share dividend in future fiscal years, despite its continuation being included in the October Management Projections.
• Mr. Pessina confirmed his willingness to consider rolling over all or part of his equity interests to facilitate the transaction, without conditioning his support on his participation.
• The Board reviewed relationship disclosures from Kirkland, Centerview, and Morgan Stanley, concluding that none of the disclosed relationships would affect their ability to serve as financial advisors.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to the ongoing shareholder lawsuits alleging material omissions and misrepresentations related to the merger. While the company denies the claims and is proceeding with supplemental disclosures, the legal challenges introduce significant uncertainty and potential delays. Furthermore, the Board's observation of declining adjusted operating income and free cash flow, coupled with the inability to cover future dividends, points to underlying financial headwinds.

Positives

• The company believes the claims asserted in the Merger Actions and Demand Letters are without merit.
• Voluntarily supplementing disclosures to moot plaintiffs' claims and avoid nuisance, potential expense, and business delays.
• The Board concluded that the relationships of financial advisors (Centerview and Morgan Stanley) and legal counsel (Kirkland) with Sycamore would not affect their ability to serve the company.
• Mr. Pessina, a key stockholder, confirmed willingness to consider rolling over equity interests to facilitate the transaction and stated he would not condition his support on his ability to participate.

Negatives

• Two lawsuits and 11 demand letters have been filed by purported stockholders alleging misrepresentation and/or omission of material information in the Definitive Proxy Statement.
• Allegations in the lawsuits include issues with financial projections, analyses performed by financial advisors, alleged conflicts of interest, and the overall merger process.
• The lawsuits generally seek to enjoin the stockholder vote on the Merger Agreement and the consummation of the Merger.
• The Board observed a decline in the company's adjusted operating income and free cash flow since 2022 due to headwinds in the U.S. retail pharmacy and healthcare businesses.
• Expected free cash flow is projected to be insufficient to cover the $1.00 per share dividend in future fiscal years.
• There is a significant risk of disruption to the company’s relationships with its employees, business counterparties, and other stakeholders due to transaction discussions.
• The company acknowledges that additional similar lawsuits and/or demand letters arising out of the Merger may be filed or received in the future.

Risks

• The proposed transaction may not be completed in a timely manner or at all.
• Affiliates of Sycamore Partners may not obtain the necessary financing arrangements.
• Failure to satisfy any of the conditions to the consummation of the proposed transaction, including regulatory and stockholder approval.
• Occurrence of any event, change, or circumstance that could lead to the termination of transaction agreements, potentially requiring the company to pay a termination fee.
• The announcement or pendency of the proposed transaction may negatively affect the company's business relationships, operating results, and business generally.
• The proposed transaction may disrupt the company's current plans and operations.
• Challenges in retaining and hiring key personnel and maintaining relationships with key business partners and customers.
• Diverting management's attention from ongoing business operations.
• Significant or unexpected costs, charges, or expenses resulting from the proposed transaction.
• Potential litigation relating to the proposed transaction that could be instituted against the parties or their directors, managers, or officers.
• Uncertainties related to the continued availability of capital and financing and rating agency actions.
• Certain restrictions during the pendency of the proposed transaction may impact the company's ability to pursue business opportunities or strategic transactions.
• Uncertainty as to the timing of completion of the proposed transaction.
• Holders of Divested Asset Proceed Rights may receive less-than-anticipated payments or no payments, and such rights may expire valueless.
• Impact of adverse general and industry-specific economic and market conditions.
• The possibility that alternative transaction proposals will or will not be made.
• The risk that the company's stock price may decline significantly if the merger is not completed.

Future Outlook

The company's financial projections for fiscal years up to 2029/2030 reflect management's assumptions regarding trends in retail sales, debt refinancing, performance of the VPMC Group, cost optimization, prescription reimbursement pressures, opioid payment obligations, and the impact of store closures from the footprint optimization program. Despite these projections, the Board noted that expected free cash flow would be insufficient to cover the historical $1.00 per share dividend in future fiscal years. The outlook is also subject to the successful consummation of the merger and resolution of ongoing litigation.

Management Comments

• Mr. Pessina confirmed to the Board that, should the Board determine a transaction with Sycamore would be in the best interests of all stockholders, he would consider taking any reasonable action necessary to facilitate such transaction, including rolling over all or part of his equity interests.
• Mr. Pessina reiterated that he would only engage in discussions with Sycamore about a potential rollover of his equity interests when appropriate and only with the Board's full knowledge and approval, and that he would not condition his support of any transaction on his ability to participate.

Industry Context

The company's U.S. retail pharmacy and healthcare businesses are facing headwinds, including prescription reimbursement pressures and the impact of store closures related to its footprint optimization program. The document highlights the uniqueness of the company's U.S. retail business in the public market, making a sum-of-the-parts analysis challenging and suggesting limited interest from other strategic or financial counterparties for a transaction of this size and varied business mix.

Comparison to Industry Standards

• Centerview's Selected Public Company Analysis compared the company to U.S. Retail companies (Albertsons Companies, Inc., CVS Health Corporation, Dollar General Corporation, Dollar Tree, Inc., Koninklijke Ahold Delhaize N.V., Target Corporation, The Kroger Co.) and International Retail companies (B&M European Value Retail SA, Frasers Group PLC, J Sainsbury PLC, Kingfisher PLC, Marks and Spencer Group P.L.C., Tesco PLC), with a total peer average EV/NTM EBITDA Trading Multiple of 5.9x.
• Centerview's Select Precedent Transaction Analysis reviewed transactions involving U.S. Grocery and North America General Retail companies (e.g., The Fresh Market, Smart & Final Stores, Supervalu Inc., Whole Foods Market, Inc., Save-A-Lot, Roundys, Inc., Nordstrom, Inc., Staples, Inc., Belk, Inc.), with a total median TEV/LTM EBITDA Multiple of 6.9x.
• Morgan Stanley's Public Trading Comparables Analysis assessed the company against comparable segments and companies including CVS Health Corporation, other U.S. Retailers (The Kroger Co., Target Corporation, Dollar General Corporation, Dollar Tree, Inc., Albertsons Companies, Inc.), International retailers (Fielmann Group AG, Ulta Beauty Inc., Tesco PLC, Marks and Spencer Group P.L.C.), and Distributors (McKesson Corporation, Cencora, Inc., Cardinal Health, Inc.).

Corporate Governance

Legal Proceedings

• Drulias v. Babiak, et al., No. 2025CH00000145 (filed June 16, 2025) in the Circuit Court for Lake County, Illinois, alleging violations of Illinois Securities Act of 1953, negligent misrepresentation, concealment, and negligence under Illinois law.
• Johnson v. Walgreens Boots Alliance, Inc., et al., C.A. No. 653635/2025 (filed June 18, 2025) in the Supreme Court of the State of New York, County of New York, alleging negligent misrepresentation and concealment, and negligence in violation of New York common law.
• Both lawsuits generally allege that the Definitive Proxy Statement misrepresents and/or omits certain purportedly material information relating to financial projections and analyses performed by the company's financial advisors, alleged conflicts of interest, and the Merger process.
• The lawsuits generally seek to enjoin the vote of Company stockholders to adopt the Merger Agreement and the consummation of the Merger unless and until certain additional information is disclosed, along with costs of the actions, including plaintiffs' attorneys' fees and experts' fees.
• The company has received 11 demand letters (with one including a draft complaint) from purported stockholders seeking additional disclosures in the Definitive Proxy Statement.
• The company believes the claims asserted in the Merger Actions and the Demand Letters are without merit but cannot predict the outcome of such claims.
• Additional lawsuits and demand letters arising out of the Merger may also be filed or received in the future.

Related Party Transactions

• Mr. Pessina, a significant existing stockholder, indicated he would consider rolling over all or part of his equity interests to facilitate the proposed transaction with Sycamore, should the Board deem it in the best interests of all stockholders.
• Kirkland, the company's legal counsel, disclosed relationships with Sycamore, including Sycamore being a client with multiple concurrent engagements unrelated to the company, and certain Kirkland partners being investors in one or more investment funds affiliated with Sycamore.

Stakeholder Impact

• Shareholders: Directly impacted by the proposed merger, the stockholder vote, and the ongoing litigation which could affect the transaction's terms or completion. Concerns exist regarding the sufficiency of future free cash flow to cover dividends.
• Employees: Potential for disruption to relationships and operations due to the pendency of the proposed transaction.
• Business Counterparties: Risk of disruption to relationships due to the proposed transaction.
• Customers: Risk of disruption to relationships due to the proposed transaction.
• Creditors: Uncertainties related to the continued availability of capital and financing and potential rating agency actions.
• Regulatory Authorities: Involved in the approval process for the merger and potentially in addressing the allegations raised in the lawsuits.

Next Steps

• A special meeting of the Company's stockholders is scheduled for July 11, 2025, to vote to adopt the Merger Agreement.
• The company may file or furnish other documents with the SEC regarding the proposed transaction.
• Additional lawsuits and demand letters arising out of the Merger may be filed or received in the future.

Key Dates

Recommendation

Keywords

Walgreens Boots Alliance, WBA, Merger, Acquisition, Sycamore Partners, Proxy Statement, SEC Filing, Shareholder Lawsuits, Financial Projections, Valuation, Retail Pharmacy, Healthcare, Corporate Governance, Risk Management, Dividend Policy, Free Cash Flow, Adjusted EBITDA